ライフサイエンスコーパス: frontotemporal

1 Seizure origins are located in the frontotemporal and limbic structures.

2 ects upper and lower motor neurons, but also frontotemporal and other regions of the brain.

3 GMD reductions, with the largest effects in frontotemporal and parietal regions; psychotic bipolar p

4 associated with higher GM-NDI mainly in the frontotemporal areas.

5 e amygdala as a critical hub, likely through frontotemporal connections indexing stimulus salience.

6 changes in SZ (e.g., hippocampus volume and frontotemporal cortical thickness), and were highly cons

7 Stronger frontoparietal and frontotemporal coupling was found in patients with defic

8 e of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) (c9ALS/FTD).

9 ated with neurodegenerative diseases such as frontotemporal degeneration and Alzheimer disease.

10 icularly associated with behavioural variant frontotemporal dementia (40% of symptomatic cases) and h

11 articularly prevalent in behavioural variant frontotemporal dementia (71% of cases) and semantic deme

12 d the patients with vascular dementia (91%), frontotemporal dementia (94%), Parkinson's disease demen

13 tions in ubiquilin 2 (UBQLN2) cause ALS with frontotemporal dementia (ALS-FTD).

14 myotrophic lateral sclerosis with associated frontotemporal dementia (ALS/FTD) are major neurodegener

15 portion of patients with behavioural variant frontotemporal dementia (bvFTD) develop amyotrophic late

16 lzheimer disease (AD) and behavioral variant frontotemporal dementia (bvFTD) in individual patients b

17 indicating a subclinical behavioural-variant frontotemporal dementia (bvFTD) in some patients.

18 agnosis in patients with behavioural variant frontotemporal dementia (bvFTD) poses a daunting challen

19 ypic heterogeneity within behavioral variant frontotemporal dementia (bvFTD) will help uncover underl

20 were diagnosed with (1) behavioural variant frontotemporal dementia (bvFTD), (2) right temporal vari

21 of the core features of behavioural variant frontotemporal dementia (bvFTD), a neurodegenerative dis

22 The behavioral variant of frontotemporal dementia (bvFTD), featuring progressive a

23 on (EF) in patients with behavioural variant frontotemporal dementia (bvFTD), primary progressive aph

24 hat exists between early behavioural variant frontotemporal dementia (bvFTD)--the most common clinica

25 sample of patients with behavioural variant frontotemporal dementia (bvFTD).

26 sample of patients with behavioural variant frontotemporal dementia (bvFTD).

27 regarding progression in behavioral variant frontotemporal dementia (BVFTD).

28 n cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD), however, the precis

29 c cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD).

30 c cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD).

31 f72 causes amyotrophic lateral sclerosis and frontotemporal dementia (c9FTD/ALS).

32 associated amyotrophic lateral sclerosis and frontotemporal dementia (C9RAN) and at CGG repeats that

33 ]; median age, 62.5 years), 20 patients with frontotemporal dementia (FTD) (8 men [4.5%] and 12 women

34 Tauopathies, including frontotemporal dementia (FTD) and Alzheimer's disease (A

35 ns in C9ORF72, are abundant in patients with frontotemporal dementia (FTD) and amyotrophic lateral sc

36 72) gene is the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sc

37 protein homeostasis have been identified in frontotemporal dementia (FTD) and amyotrophic lateral sc

38 nsions are the most common cause of familial frontotemporal dementia (FTD) and amyotrophic lateral sc

39 ial function has been found in patients with frontotemporal dementia (FTD) and amyotrophic lateral sc

40 er's disease (AD), Lewy body dementia (LBD), frontotemporal dementia (FTD) and Huntington's disease (

41 of patients with Alzheimer's disease (AD) or frontotemporal dementia (FTD) and matched cognitively no

42 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are age-related neurodegen

43 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping neurodegen

44 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping, fatal neu

45 Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are related neurodegenerat

46 viewed all neuroimaging studies of apathy in frontotemporal dementia (FTD) attempting to refine a neu

47 are similar to Alzheimer's disease (AD) and frontotemporal dementia (FTD) cases, and LSD1 is specifi

48 Frontotemporal dementia (FTD) encompasses a group of neu

49 profiling to demonstrate that deficiency in frontotemporal dementia (FTD) gene progranulin (Grn) lea

50 Frontotemporal dementia (FTD) is a neurodegenerative dis

51 Frontotemporal dementia (FTD) is the second most common

52 e in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) presents a significant res

53 Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) share overlapping genetic

54 ese features in Alzheimer's disease (AD) and frontotemporal dementia (FTD) spectrum disorders, at fir

55 Loss-of-function mutations in GRN cause frontotemporal dementia (FTD) with transactive response

56 s having ALS with normal cognition, ALS with frontotemporal dementia (FTD), ALS with executive or non

57 logical and genetic overlap between sporadic frontotemporal dementia (FTD), Alzheimer's disease (AD)

58 disease (PD) and Huntington's disease (HD), frontotemporal dementia (FTD), amyotrophic lateral scler

59 ations in GRN, the gene encoding PGRN, cause frontotemporal dementia (FTD), and a GRN SNP confers sig

60 h AD, 20 patients with DM2, 16 patients with frontotemporal dementia (FTD), and matched case control

61 ive diseases such as Alzheimer disease (AD), frontotemporal dementia (FTD), and progressive supranucl

62 d in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), as it was demonstrated th

63 LS) exhibit cognitive deficits indicative of frontotemporal dementia (FTD), suggesting a common patho

64 Frontotemporal dementia (FTD), the second most common fo

65 various neurodegenerative diseases including frontotemporal dementia (FTD), which can be caused by mu

66 eating behaviors are common in patients with frontotemporal dementia (FTD), yet their exact prevalenc

67 Frontotemporal dementia (FTD)-causing mutations in the C

68 ses in in vivo and in vitro models of AD and frontotemporal dementia (FTD).

69 both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

70 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

71 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

72 the most frequent cause of familial ALS and frontotemporal dementia (FTD).

73 n in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

74 m in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

75 d in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

76 of patients with Alzheimer's disease (AD) or frontotemporal dementia (FTD).

77 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

78 f72) subjects with a pathogenic mutation for frontotemporal dementia (FTD).

79 generation due to a tau mutation that causes frontotemporal dementia (FTD).

80 ochondria of neurons in subjects with ALS or frontotemporal dementia (FTD).

81 Alzheimer disease (AD) but not a feature of frontotemporal dementia (FTD).

82 lial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

83 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

84 ical, pathological, and genetic overlap with frontotemporal dementia (FTD).

85 e in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

86 oach to amyotrophic lateral scleorosis (ALS)/frontotemporal dementia (FTD).

87 is the most common genetic cause of ALS and frontotemporal dementia (FTD).

88 mes, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

89 al ALS (fALS), sporadic ALS (sALS), ALS with frontotemporal dementia (FTD-ALS), and Alzheimer's disea

90 Other neurodegenerative diseases, such as frontotemporal dementia (FTD; n = 30), Parkinson's disea

91 inclusion body myopathy, Paget disease with frontotemporal dementia (IBMPFD) and other neurodegenera

92 sease biomarker-negative behavioural variant frontotemporal dementia (n = 59), and controls (n = 61).

93 dementia (bvFTD), (2) right temporal variant frontotemporal dementia (rtFTD), (3) semantic variant of

94 65-year-old female with behavioural variant frontotemporal dementia accompanied by focal degeneratio

95 fects, respectively, in clinical subtypes of frontotemporal dementia against neurologically normal co

96 spite being criteria for behavioural variant frontotemporal dementia alone.

97 roup of 25 patients with behavioural variant frontotemporal dementia and 21 control subjects, diagnos

98 Game in 22 patients with behavioural variant frontotemporal dementia and 22 age-matched controls, to

99 articipating in the Genetic Investigation in Frontotemporal Dementia and Alzheimer's Disease (GIFT) S

100 ed synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease.

101 poradic neurodegenerative diseases including frontotemporal dementia and Alzheimer's disease.

102 ich is both deficient in behavioural variant frontotemporal dementia and closely associated with inhi

103 s did not differ between behavioural variant frontotemporal dementia and controls for pleasant or neu

104 oncept of progranulin-boosting therapies for frontotemporal dementia and highlight an important role

105 ch has not been tested in an animal model of frontotemporal dementia and it is unclear if boosting pr

106 of the reward deficit in behavioural variant frontotemporal dementia and its underlying anatomy.

107 tiple neurodegenerative disorders, including frontotemporal dementia and parkinsonism linked to chrom

108 son's, and Huntington's diseases, as well as frontotemporal dementia and prion diseases.

109 ificantly higher risk for clinically defined frontotemporal dementia and progressive supranuclear pal

110 Behavioural variant frontotemporal dementia and semantic variant primary pro

111 st analysis restricted to behavioral variant frontotemporal dementia and semantic variant primary pro

112 vioural disinhibition in behavioural variant frontotemporal dementia and the effect of selective sero

113 ith C9orf72 in amyotrophic lateral sclerosis/frontotemporal dementia and with polyglutamine diseases,

114 yndrome shares pathobiological features with frontotemporal dementia and, indeed, many patients show

115 rrying a C9orf72 repeat expansion leading to frontotemporal dementia and/or amyotrophic lateral scler

116 GGGGCC repeat expansion in C9orf72 leads to frontotemporal dementia and/or amyotrophic lateral scler

117 results showed that Alzheimer's disease and frontotemporal dementia are associated with distinct and

118 n Alzheimer's Disease (AD) brains but not in frontotemporal dementia brains.

119 e inhibition deficits in behavioural variant frontotemporal dementia can be partially restored by inc

120 iation studies on 3348 clinically identified frontotemporal dementia cases and 9390 controls (discove

121 observational study, 90 patients meeting the Frontotemporal Dementia Consortium consensus criteria fo

122 ed resting heart rate in behavioural variant frontotemporal dementia correlated with atrophy involvin

123 Though patients with behavioural variant frontotemporal dementia display changes in their pursuit

124 deficits in Grn+/- mice, an animal model of frontotemporal dementia due to GRN mutations.

125 , we describe two illuminating patients with frontotemporal dementia due to the C9orf72 repeat expans

126 Family caregivers of patients with frontotemporal dementia experience significant distress,

127 Family caregivers of patients with frontotemporal dementia face unique challenges due to it

128 Family caregivers of patients with frontotemporal dementia identify behavioral disturbances

129 the understanding of the molecular basis for frontotemporal dementia improves, rational therapies are

130 body myopathy, Paget's disease of bone, and frontotemporal dementia in humans unfolds substrate fast

131 E-locus association with behavioural variant frontotemporal dementia indicates its potential risk-inc

132 Frontotemporal dementia is a common type of dementia, pa

133 Frontotemporal dementia is a heterogeneous neurodegenera

134 Frontotemporal dementia is a highly heritable neurodegen

135 ly been established that behavioural variant frontotemporal dementia is associated with abnormal eati

136 Frontotemporal dementia is thought to be the second most

137 4 we described an Irish-American family with frontotemporal dementia linked to chromosome 17 associat

138 A>C variant is a mutation and that it causes frontotemporal dementia linked to chromosome 17 in this

139 In tauopathy-frontotemporal dementia mice, both drugs were neuroprote

140 it was hypothesized that behavioural variant frontotemporal dementia might also be associated with al

141 atrophy in presymptomatic carriers of common frontotemporal dementia mutations is affected by both ge

142 as frontotemporal dementia, non-amnestic as frontotemporal dementia or corticobasal degeneration, an

143 We also used a frontotemporal dementia patient-derived induced pluripot

144 e the role of p25/Cdk5 in tauopathy, we used frontotemporal dementia patient-derived induced pluripot

145 be a modifier of the age at disease onset in frontotemporal dementia patients with TDP-43 pathology.

146 ealed that patients with behavioural variant frontotemporal dementia rated unpleasant odours as less

147 hometry of patients with behavioural variant frontotemporal dementia revealed that the inability to s

148 Genome-wide association studies in frontotemporal dementia showed limited success in identi

149 nt p.A152T was reported as a risk factor for frontotemporal dementia spectrum and Alzheimer's disease

150 study has tested this hypothesis in vivo in frontotemporal dementia spectrum disorders.

151 ations in the gene encoding tau (MAPT) cause frontotemporal dementia spectrum disorders.

152 ed in sarcoma (FUS) are hallmarks of ALS and frontotemporal dementia subtypes.

153 tion for epilepsy 5 years prior to her first frontotemporal dementia symptoms.

154 GRN mutations are thought to cause frontotemporal dementia through progranulin haploinsuffi

155 lthcare providers who care for patients with frontotemporal dementia to recognize the unique needs of

156 Behavioural variant frontotemporal dementia was associated with decreased ac

157 Behavioral variant frontotemporal dementia was the predominant clinical phe

158 ion score, patients with behavioural variant frontotemporal dementia were less averse to losses than

159 stimulus, patients with behavioural variant frontotemporal dementia were less motivated, and therefo

160 antic dementia) are two clinical variants of frontotemporal dementia with overlapping but distinct an

161 ranuclear palsy, eight Pick's disease, three frontotemporal dementia with parkinsonism associated wit

162 Mutations in the tau gene MAPT cause frontotemporal dementia with parkinsonism linked to chro

163 el expresses a human tau protein bearing two frontotemporal dementia with Parkinsonism linked to chro

164 Mutations in the MAPT gene cause frontotemporal dementia with Parkinsonism linked to chro

165 familial etiology, such as in some cases of frontotemporal dementia with parkinsonism.

166 TB is significantly altered in patients with frontotemporal dementia with TDP-43-positive inclusions

167 istics of family caregivers of patients with frontotemporal dementia, (2) explore the impact of provi

168 hort of 19 patients with behavioural variant frontotemporal dementia, 13 with Alzheimer's disease and

169 esented 28 patients with behavioural variant frontotemporal dementia, 14 patients with semantic varia

170 generative lesion model: behavioural variant frontotemporal dementia, a condition characterized by gr

171 ia, are a common autosomal dominant cause of frontotemporal dementia, a neurodegenerative disease com

172 9 developed dementia due to AD, 2 developed frontotemporal dementia, and 1 developed moderate dement

173 tia (eg, senile dementia, vascular dementia, frontotemporal dementia, and Alzheimer dementia).

174 changes are prevalent in behavioural variant frontotemporal dementia, and are associated with changes

175 of APOE and TOMM40 with behavioural variant frontotemporal dementia, and ARHGAP35 and SERPINA1 with

176 is uniquely impaired in behavioural variant frontotemporal dementia, and may explain other common fe

177 rd-seeking behaviours in behavioural variant frontotemporal dementia, and may relate to degeneration

178 implicated in amyotrophic lateral sclerosis, frontotemporal dementia, and multisystem proteinopathy-d

179 ve impairment, Alzheimer's disease dementia, frontotemporal dementia, and vascular dementia.

180 n in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, but it is unknown whether loss

181 M106B are thought to modify disease onset in frontotemporal dementia, but its relation to myelination

182 avioural profile than in behavioural variant frontotemporal dementia, co-occurrence of memory dysfunc

183 In the vascular dementia, frontotemporal dementia, dementia with Lewy bodies and P

184 lzheimer disease, n = 16; behavioral variant frontotemporal dementia, n = 13).

185 gative cases were most often reclassified as frontotemporal dementia, non-amnestic as frontotemporal

186 ehavioural symptoms span a range from ALS to frontotemporal dementia, present an opportunity to evalu

187 rdinal feature of the behavioural variant of frontotemporal dementia, presenting as impulsive and imp

188 t spans behavioural and language variants of frontotemporal dementia, progressive supranuclear palsy

189 r treating or preventing such tauopathies as frontotemporal dementia, progressive supranuclear palsy,

190 In behavioural variant frontotemporal dementia, resting (P = 0.001), stressed (

191 the network involved in eating behaviour in frontotemporal dementia, suggesting a complex interactio

192 models of amyotrophic lateral sclerosis and frontotemporal dementia, that TDP-43 impairs the inducti

193 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, though the mechanisms by which

194 d with the spectrum of familial and sporadic frontotemporal dementia-amyotrophic lateral sclerosis (F

195 ticle other mutations were reported to cause frontotemporal dementia-amyotrophic lateral sclerosis sy

196 ase 2 was a 74-year-old female with atypical frontotemporal dementia-motor neuron disease who underwe

197 f neuronal progranulin in the development of frontotemporal dementia-related deficits, we generated t

198 ge cohort of presymptomatic subjects bearing frontotemporal dementia-related pathogenic mutations.

199 S or related TDP-43 proteinopathies, such as frontotemporal dementia.

200 nd the accepted relationship between ALS and frontotemporal dementia.

201 course in a discussion of behavioral variant frontotemporal dementia.

202 ead to multisystem proteinopathies including frontotemporal dementia.

203 including amyotrophic lateral sclerosis and frontotemporal dementia.

204 have previously been associated with risk of frontotemporal dementia.

205 s of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

206 lbeing of family caregivers of patients with frontotemporal dementia.

207 ene causes amyotrophic lateral sclerosis and frontotemporal dementia.

208 c cause of amyotrophic lateral sclerosis and frontotemporal dementia.

209 nsufficiency are prevalent genetic causes of frontotemporal dementia.

210 the clinicopathological overlap of ALS with frontotemporal dementia.

211 clusion body myopathy with Paget disease and frontotemporal dementia.

212 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

213 ive diseases such as Alzheimer's disease and frontotemporal dementia.

214 genesis of amyotrophic lateral sclerosis and frontotemporal dementia.

215 ntify whether such changes could be shown in frontotemporal dementia.

216 c cause of amyotrophic lateral sclerosis and frontotemporal dementia.

217 ms in asymptomatic adults at risk of genetic frontotemporal dementia.

218 ic criteria for possible behavioural-variant frontotemporal dementia.

219 Genetics is an important risk factor for frontotemporal dementia.

220 f familial amyotrophic lateral sclerosis and frontotemporal dementia.

221 sources were impaired by behavioural variant frontotemporal dementia.

222 ding amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

223 lusively in social and emotion processing in frontotemporal dementia.

224 gnosis of Alzheimer's disease (AD, n = 289), frontotemporal dementia/amyotrophic lateral sclerosis (F

225 ressing transgenic (P301S-tg) mouse model of frontotemporal dementia/tauopathy.

226 ng Alzheimer's disease; tauopathies, such as frontotemporal dementia; alpha-synucleinopathies, such a

227 ss) can be maintained in behavioural variant frontotemporal dementia; however, more complex normative

228 s healthy controls, with primarily anterior (frontotemporal) effects in Biotype1; posterior (temporo-

229 actable epilepsy who had extensive bilateral frontotemporal electrode coverage while breathing was mo

230 omprehension activates only the auditory and frontotemporal (FTN) syntax networks, performing a simpl

231 Genotype effects were not observed in frontotemporal GM volume.

232 expectancy input at the higher level of the frontotemporal hierarchy.

233 Extensive frontotemporal hypometabolism was predictive for a lower

234 howed that intentional harm induced stronger frontotemporal information sharing at early stages.

235 vision, the "VWFA" is incorporated into the frontotemporal language network and participates in high

236 topic cortices and linguistic input from the frontotemporal language network because reading involves

237 mpensatory activation of regions outside the frontotemporal language network, we use a novel systems-

238 l tau deposition were identified starting in frontotemporal limbic/paralimbic and neocortical regions

239 abundance of mature tau pathology markers in frontotemporal limbic/paralimbic regions compared to neo

240 or disorder, ALS can arise concurrently with frontotemporal lobal dementia (FTLD).

241 s correlate with postmortem tau pathology in frontotemporal lobar degeneration (FTLD) and (2) tauopat

242 neuropathologic entities, including forms of frontotemporal lobar degeneration (FTLD) or Alzheimer di

243 aphasia (svPPA) is typically associated with frontotemporal lobar degeneration (FTLD) with longTAR DN

244 l FTD cases are classified pathologically as frontotemporal lobar degeneration (FTLD) with TAR DNA-bi

245 uopathies, include Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD) with tau pathol

246 linical diagnosis of PPA was associated with frontotemporal lobar degeneration (FTLD) with transactiv

247 98 with a primary pathological diagnosis of frontotemporal lobar degeneration (FTLD), 15 with Alzhei

248 mutations in the granulin (GRN) gene causes frontotemporal lobar degeneration (FTLD), and complete l

249 ic ALS, ALS mimics (disease controls (DCo)), frontotemporal lobar degeneration (FTLD), Creutzfeldt-Ja

250 ost common clinical syndrome associated with frontotemporal lobar degeneration (FTLD)--and several pr

251 inclusions in TDP-43 proteinopathies such as frontotemporal lobar degeneration (FTLD)-TDP are made of

252 s of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).

253 e of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).

254 common neurodegenerative disorders including frontotemporal lobar degeneration (FTLD).

255 Mutant Tau (MAPT) can lead to frontotemporal lobar degeneration (FTLD).

256 izes amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP).

257 or temperature for a cohort of patients with frontotemporal lobar degeneration (n = 58, 25 female, ag

258 f-function mutations in the PGRN gene causes frontotemporal lobar degeneration accompanied by TDP-43

259 th risk of neurodegenerative diseases beyond frontotemporal lobar degeneration are enriched in CTCF-b

260 c lateral sclerosis and approximately 60% of frontotemporal lobar degeneration cases.

261 the voxel-based morphometry analysis of the frontotemporal lobar degeneration cohort, pain and tempe

262 to complex behavioural changes arising from frontotemporal lobar degeneration provides new insights

263 to clinical phenotypes, particularly in the frontotemporal lobar degeneration spectrum, but the basi

264 tive components of apathy and impulsivity in frontotemporal lobar degeneration syndromes.

265 ligand [(18)F]AV-1451, which is elevated in frontotemporal lobar degeneration tauopathies.

266 amilial neurodegenerative disorder, known as frontotemporal lobar degeneration tauopathy (FTLD-Tau),

267 Frontotemporal lobar degeneration with TDP-43 inclusions

268 esulting in protein haploinsufficiency cause frontotemporal lobar degeneration with TDP-43 inclusions

269 Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin positiv

270 s of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin-positiv

271 dementia with Lewy bodies, 55 patients with frontotemporal lobar degeneration), and scans from 73 he

272 veral neurodegenerative disorders, including frontotemporal lobar degeneration, amyotrophic lateral s

273 ies including amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and sporadic inclusio

274 racteristic of human Alzheimer's disease and frontotemporal lobar degeneration, including beta-amyloi

275 nalysis of the 7p21 locus linked by GWASs to frontotemporal lobar degeneration, nominating a causal v

276 pathological diagnosis of Alzheimer disease, frontotemporal lobar degeneration-tau, frontotemporal lo

277 ease, frontotemporal lobar degeneration-tau, frontotemporal lobar degeneration-transactive response D

278 o differentiate and track different types of frontotemporal lobar degeneration.

279 ity are common and disabling consequences of frontotemporal lobar degeneration.

280 ne were identified in patients with familial Frontotemporal Lobar Degeneration.

281 us and risk of the neurodegenerative disease frontotemporal lobar degeneration.

282 hic lateral sclerosis and ubiquitin-positive frontotemporal lobar degeneration.

283 s of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Dementia (FTLD).

284 ions of the C9orf72 gene were found in major frontotemporal lobar dementia and amyotrophic lateral sc

285 disease, amyotrophic lateral sclerosis, and frontotemporal lobar dementia are among the most pressin

286 es, including amyotrophic lateral sclerosis, frontotemporal lobar dementia, and Alzheimer's disease.

287 including amyotrophic lateral sclerosis and frontotemporal lobar dementia.

288 Our study shows that, by early childhood, frontotemporal (long segment) and frontoparietal (anteri

289 e comprehension solely recruits auditory and frontotemporal networks, the latter of which is similarl

290 (GM and WM, respectively) structure within a frontotemporal neural system implicated in BD.

291 We propose that an impaired top-down frontotemporal projection is responsible for this disord

292 Frontotemporal region of interest (ROI) and whole-brain

293 ar volume and cerebral cortical thickness in frontotemporal regions (i.e., overlapping with areas tha

294 e reductions in grey matter and perfusion of frontotemporal regions, and increases in white matter an

295 correlated with higher beta/gamma power over frontotemporal regions.

296 eric expression profiles are associated with frontotemporal regions.

297 ions, with the largest effects in insula and frontotemporal regions; and Biotype3, small reductions l

298 FA reductions in forceps and frontotemporal tracts correlated inversely with symptom

299 pathologies demonstrated similar patterns of frontotemporal volume loss, although less extensive on t

300 ese findings support effects of rs9804190 on frontotemporal WM in adolescents and adults with BD and